Group 1: Financial Performance - The company achieved a revenue of 713 million CNY, representing an increase of 11.02% compared to the same period last year [3] - Medical device business revenue reached approximately 482 million CNY, growing by 13.8% [3] - The net profit attributable to shareholders was approximately 74 million CNY, with a year-on-year growth of about 20.99% after excluding stock incentive expenses and exchange losses [3] Group 2: Business Operations - The company focuses on management-style medical services, primarily in the liver disease sector, including drug production, diagnostic equipment development, and related medical services [3] - Echosens has installed a total of 977 units of its products globally [3] - The company is currently collaborating with Novo Nordisk to promote early diagnosis and treatment of Metabolic Associated Steatotic Hepatitis (MASH) [3] Group 3: Market Trends and Strategies - The approval of semaglutide for MASH is expected to enhance awareness and treatment options in the industry [3] - The company has stable internal shareholding and strategic plans, indicating no adjustments to its operational strategies [4] - E-commerce channels for traditional Chinese medicine have shown significant growth, with a year-on-year increase of 59.23% [4] Group 4: Future Outlook - The company's mission is to "keep every family away from liver cancer," focusing on a closed-loop management strategy to reduce liver cancer incidence [5] - There is confidence in the industry outlook and the company's development trajectory, supported by a clear organizational and shareholding structure [5]

New Stock Listings - New stock "能之光" (Code: 920056) listed at an issue price of 7.21 on August 22, 2025[1] - "申科股份" (Code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - "抚顺特钢" (Code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - "赛诺医疗" (Code: 688108) reported severe abnormal fluctuations on August 19, 2025[1] - "ST苏吴" (Code: 600200) announced abnormal fluctuations on August 21, 2025[1] - "汇嘉时代" (Code: 603101) reported abnormal fluctuations on August 22, 2025[1] Other Notable Announcements - "酒鬼酒" (Code: 000799) reported an announcement on August 21, 2025[1] - "国机精工" (Code: 002046) had an announcement on August 21, 2025[1] - "全柴动力" (Code: 600218) reported an announcement on August 21, 2025[1]

Core Viewpoint - The stock price of Furuya Co., Ltd. has declined by 4.63% as of August 21, 2025, despite a year-on-year revenue growth of 11.0% in the first half of 2025, indicating potential concerns regarding profitability and market sentiment [1]. Financial Performance - The company's revenue for the first half of 2025 reached 713 million yuan, reflecting an 11.0% increase compared to the previous year [1]. - The net profit attributable to shareholders was 51.93 million yuan, showing a significant decline of 31.1% year-on-year [1]. - The medical device segment generated revenue of 482 million yuan, up 13.8%, while the pharmaceutical and medical services segments reported revenue of 231 million yuan, an increase of 5.62% [1]. Cost and Loss Factors - The company incurred stock incentive expenses of 12.44 million yuan and foreign exchange losses of 28.55 million yuan due to currency fluctuations during the reporting period [1]. - Excluding these factors, the net profit would have increased by 20.99% year-on-year [1]. Market Activity - On August 21, 2025, the main funds experienced a net outflow of 129.02 million yuan, accounting for 0.81% of the circulating market value [1]. - Over the past five days, the cumulative net outflow of main funds reached 434.79 million yuan, representing 2.74% of the circulating market value [1]. Corporate Governance - On August 21, 2025, the company held its 14th meeting of the 8th Board of Directors to review matters including the proposal for a temporary shareholders' meeting [1].

Core Insights - The company reported a revenue of 713 million yuan for the first half of 2025, representing a year-on-year increase of 11.02% [1] - The net profit attributable to shareholders decreased to 51.934 million yuan, a decline of 31.09% compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 53.323 million yuan, down 28.39% year-on-year [1] - The basic earnings per share stood at 0.1972 yuan [1]

Group 1 - The company Furuya Co., Ltd. (SZ 300049) announced on August 21 that its 14th meeting of the 8th board of directors was held via communication, discussing the proposal for the second extraordinary shareholders' meeting of 2025 [2] - For the fiscal year 2024, the company's revenue composition is 100% from the medical sector [2]

（文章来源：每日经济新闻） 福瑞股份（SZ 300049，收盘价：68元）8月21日晚间发布半年度业绩报告称，2025年上半年营业收入约 7.13亿元，同比增加11.02%；归属于上市公司股东的净利润约5193万元，同比减少31.09%；基本每股收 益0.1972元，同比减少31.17%。 ...

内蒙古福瑞医疗科技股份有限公司 重大信息内部保密制度 内蒙古福瑞医疗科技股份有限公司 重大信息内部保密制度 第六条 本制度所指重大信息包括但不限于《内蒙古福瑞医疗科技股份有限公司重大信息 内部报告制度》《内蒙古福瑞医疗科技股份有限公司内幕信息知情人登记备案制度》中所列 重大信息、内幕信息。 第七条 公司董事、高级管理人员、公司各部门及相关工作人员均应做好重大信息的保密 1 内蒙古福瑞医疗科技股份有限公司 重大信息内部保密制度 工作。 第一条 为规范内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）的内幕信息管理， 加强公司重大信息内部保密工作，根据《中华人民共和国公司法》《中华人民共和国证券法》 《深圳证券交易所创业板股票上市规则（2025年修订）》等相关法律、法规以及《深圳证券 交易所上市公司自律监管指引第2号——创业板上市公司规范运作（2025年修订）》《内蒙古 福瑞医疗科技股份有限公司章程》（以下简称《公司章程》）等相关规定，制定本制度。 第二条 公司董事会是公司重大信息内部保密工作的管理机构。 第三条 董事会秘书为公司重大信息保密工作的负责人。董事会办公室具体负责公司重大 信息内部保密工作的监管及信息 ...

内蒙古福瑞医疗科技股份有限公司 董事会议事规则 二〇二五年八月 内蒙古福瑞医疗科技股份有限公司 董事会议事规则 | | | 内蒙古福瑞医疗科技股份有限公司 董事会议事规则 第一章 总则 第一条 为了更好地发挥董事会的作用，建立完善的法人治理结构，以确保董事会的工 作效率和科学决策，明确相应的责任，保证董事会议程和决议的合法化，根据《中华人民 共和国公司法》（以下简称《公司法》）、中国证券监督管理委员会《上市公司章程指引》 《深圳证券交易所创业板股票上市规则（2025 年修订）》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作（2025 年修订）》及《内蒙古福瑞医疗科技 股份有限公司章程》（以下简称《公司章程》）的有关规定，制定本规则。 第二条 董事会是公司常设的执行机构，行使法律或《公司章程》规定及股东会授予的 职权。 董事会由 5 名董事组成，设董事长 1 人。 公司董事会下设战略发展委员会、审计委员会、提名委员会、人力资源与薪酬委员会 等专门委员会。各专门委员会就专门性事项进行研究，提出意见及建议，供董事会决策参 考。各专门委员会对董事会负责，各专门委员会的提案应提交董事会审查决 ...

内蒙古福瑞医疗科技股份有限公司 募集资金管理办法 第一章 总则 内蒙古福瑞医疗科技股份有限公司 募集资金管理办法 第一条 为了规范内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）募集资金的管 理和使用，保护投资者的利益，根据《中华人民共和国公司法》《中华人民共和国证券法》 等法律法规、规章制度及《上市公司募集资金监管规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作（2025 年修订）》《内蒙古福瑞医疗科技 股份有限公司章程》（以下简称《公司章程》）等相关规定，结合公司实际情况，制定本 办法。 第二条 本办法所称募集资金是指，公司通过发行股票或者其他具有股权性质的证 券，向投资者募集并用于特定用途的资金，但不包括公司为实施股权激励计划募集的资金。 第三条 募集资金的使用应坚持周密计划、精打细算、规范运作、公开透明的原则。 第四条 公司董事会应当持续关注募集资金存放、管理和使用情况，有效防范投资风 险，提高募集资金使用效益。 公司的董事、高级管理人员应当勤勉尽责，确保公司募集资金安全，不得操控公司擅 自或变相改变募集资金用途。。 第五条 非经公司股东会依法作出决议，任何人无权改变 ...

内蒙古福瑞医疗科技股份有限公司 职务授权及代理人制度 第二条 本制度适用于公司各部门、各子公司、各控股子公司及其他所属公 司的《法定代表人身份证明书》及《授权委托书》的签发、使用和管理。 内蒙古福瑞医疗科技股份有限公司 职务授权及代理人制度 第三条 权限证书的签发和使用应当遵循准确、守制、合法的原则。未经授 权，任何人不得以其所在公司名义从事经济活动。 第二章 管理机构和人员 第四条 综合管理部负责公司《法定代表人身份证明书》和授权委托书的管 理工作，并对各子公司《法定代表人身份证明书》和授权委托书的签发、使用、 管理进行指导、监督和检查。 各子公司应当设专人负责本公司《法定代表人身份证明书》和授权委托书的 管理工作。 第一章 总则 第一条 为了加强内蒙古福瑞医疗科技股份有限公司(以下简称"公司")权 限证书管理，规范授权行为，明确经营管理权限，维护公司合法权益，根据国家 有关法律、法规和《内蒙古福瑞医疗科技股份有限公司章程》（以下简称《公司 章程》）等有关规定，结合公司实际情况，制定本制度。 第五条 公司综合管理部在权限证书管理方面的职责是： （一）起草、发布、推广权限证书示范文本； （二）办理公司法定代表 ...